Funding Advances Cancer Immunotherapy for Lynch Syndrome

Nouscom's €120 million Series D backs a global trial of NOUS-209, which remains investigational and has no approved use yet.

Updated on Nov. 6, 2026 in Biotech

Bold vector editorial illustration of a coral sphere split into clustered segments with small teal protrusions on a cream field, evoking a cell fragmenting into distinct units.
Neva SGR and Angelini Industries joined the European Investment Bank in Nouscom AG's €120 million Series D round to fund a global trial of NOUS-209 for Lynch syndrome. AI Illustration. Upload story photo >

Neva SGR, the venture capital arm of the Intesa Sanpaolo Group, invested in Swiss biotech Nouscom AG through its Neva II Fund as part of a €120 million Series D financing round. The company is developing next-generation immunotherapies, and the investment is a funding event rather than a shipped product or trial result.

Why it matters

The round funds NOUS-209, an investigational neoantigen-based cancer immunotherapy, signaling continued institutional capital flowing into personalized cancer vaccine approaches at the clinical-trial stage. The co-investment by Angelini Industries and the European Investment Bank suggests the financing is drawing both private and public-sector backing.

The round totals €120 million and is reported as a Series D, meaning the company has already raised several prior rounds. Specific clinical efficacy data for NOUS-209 was not included in the source, so no performance figures can be reported.

The players

Neva SGR S.p.A.

The venture capital company of the Intesa Sanpaolo Group, which invests through funds such as the Neva II Fund.

Nouscom AG

A Swiss biotech company developing next-generation immunotherapies, including the investigational cancer vaccine NOUS-209.

Angelini Industries

An Italian industrial and pharmaceutical group that co-invested alongside Neva SGR through Angelini Investments.

European Investment Bank

The European Union's public lending institution, which co-invested through Aurea, its co-investment fund with Angelini Ventures.

The details

Neoantigen-based immunotherapies are designed to train the immune system to recognize mutations unique to a patient's tumor, which are called neoantigens. NOUS-209 is being tested in a global clinical trial aimed at cancer interception, meaning preventing cancer from developing, in people with Lynch syndrome, a hereditary condition that raises the risk of several cancers. The Series D round is being used to advance that trial.

Timeline

  1. Hogan Lovells Cadwalader published its announcement of the advisory work on 6 November 2026.

The Tech Race

Neoantigen-based cancer vaccines are a competitive research area in which several companies are developing individualized immunotherapies. This Series D round positions Nouscom to advance NOUS-209 into a global trial focused on prevention in a high-risk population.

The financing does not change availability for patients, as NOUS-209 remains investigational and is being tested in a clinical trial. Timelines for trial results or any regulatory submission were not disclosed in the source.

The takeaway

Watch for enrollment announcements or early data from the global NOUS-209 trial in people with Lynch syndrome, which would show whether the immunotherapy is advancing toward a cancer-interception indication. Funding rounds like this one often precede such milestones, so trial registrations are a practical signal to track.

Further reading

For more on the research behind personalized cancer treatments, explore the Biotech section.

Source note: This article includes information reported by Hlc.